Humacyte Q4 Revenue Down 7%, Stock Falls 7%; Net Loss Widens to $24.8M

Humacyte reported a Q4 revenue of $0.5mln and a net loss of $24.8mln, compared to $20.9mln in Q4 2024. Full year revenue reached $2mln, with a net loss of $40.8mln, narrowing significantly from $148.7mln in 2024. The company ended 2025 with $50.5mln in cash and cash equivalents. Symvess, approved in December 2024, has been ordered by 27 hospitals with multiple re-orders reported. Humacyte also entered a $77.5mln credit facility and submitted an IND for CTEV, a coronary vessel for CABG, with a Phase 1 trial planned for H2 2026.